Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3094-3098
DOI: 10.1200/jco-26-01340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Vivek Subbiah und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
- Genomic Sciences and Precision Medicine Center, and Medical College of Wisconsin Cancer Center, Milwaukee, WI.
- WIN Consortium, Paris, France.
ORCID-Profile: Vivek Subbiah, Razelle Kurzrock
Zitieren
APA
Subbiah, V., & Kurzrock, R. (2026). Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement. Journal of Clinical Oncology, 44(32), 3094-3098. https://doi.org/10.1200/jco-26-01340
Vancouver
Subbiah V, Kurzrock R. Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement. Journal of Clinical Oncology. 2026;44(32):3094-3098. doi:10.1200/jco-26-01340
BibTeX
@article{Subbiah2026,
author = {Subbiah, Vivek and Kurzrock, Razelle},
title = {Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3094--3098},
doi = {10.1200/jco-26-01340}
}
EUVIMED